Millions of Women Are Getting Unregulated Hormone-Therapy Treatments
Millions of women are being prescribed hormone therapy with mostly unregulated compounds, according to a new study.
The number of prescriptions has reached an estimated 26 to 33 million a year.
That approaches the 36 million prescriptions per year for well-regulated and tested FDA-approved hormone therapy, shows an analysis of the market compounded hormone therapy market, published in Menopause, the journal of the North American Menopause Society (NAMS).
Sales of these compounded hormones have not only grown to some $1.3 to $1.6 billion but are also expected to continue to grow, despite the potential risks. Pharmacists providing these medications predicted 5% to 25% growth in the next 2 years, according to the analysis.
The sales of FDA-approved medications are tracked, but those of compounded medications are not, so the authors analyzed data from a Rose Research online survey of US pharmacists at compounding andindependent community pharmacies. Nearly 500 pharmacists (118 compounding and 365 independent community pharmacists) completed the survey, which asked about the number of compounded hormone therapy prescriptions filled, the percentage of total volume, the percentages of different types of compounded hormone therapy sold, and what growth the pharmacists expected for these medications in the next two years.
The analysts then estimated the size of the market based on the responses and the average percentage of compounding reported by the national Community Pharmacists Association and the industry market research firm IBISWorld.
The authors highlighted concerns over the lack of clinical data about the safety of compounded hormones as well as fears over the quality of these products. In fact, an investigative report published in MORE magazine showed that none of the 12 compounding pharmacy formulations tested contained the quantities of hormones prescribed. Ten contained too much of the prescribed estrogens and 11 too littleprogesterone, an imbalance that can allow overgrowth of the uterine lining and lead to cancer.
“Despite the increased quality risks and the lack of safety and efficacy data for non-FDA regulated compounded hormone therapy formulations, their use by menopausal women is higher than expected and appears to be continuing to grow,” says NAMS Executive Director Emeritus Wulf H. Utian , MD, PhD,DSc(Med).
Driving the growth of that market may be a perception that compounded formulations are safer than FDA-approved therapies, noted the authors. After 2002 when the Women’s Health Initiative trial identified health risks with one type of estrogen-progestogen therapy, prescriptions of all FDA-approvedmenopausal hormone therapies dropped precipitously. Also in 2002, a Supreme Court decision allowed pharmacies to market compounded products that were not FDA approved, allowing that market to grow.